Gene Biotherapeutics (CRXM) Short Interest Ratio & Short Volume

Short interest is the volume of Gene Biotherapeutics shares that have been sold short but have not yet been closed out or covered. As of October 15th, traders have sold 100 shares of CRXM short. Learn More on Gene Biotherapeutics' current short interest.

Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to Gene Biotherapeutics: Amgen Inc. (1.75%), Gilead Sciences, Inc. (1.33%), argenx SE (2.98%), BioNTech SE (1.02%), Biogen Inc. (2.12%), Moderna, Inc. (9.70%), Neurocrine Biosciences, Inc. (2.59%), Bio-Techne Co. (2.27%), Vaxcyte, Inc. (8.37%), Qiagen (1.77%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.14 billion), AppLovin Co. ($3.15 billion), Paychex, Inc. ($2.69 billion), Nu Holdings Ltd. ($2.48 billion), Cencora, Inc. ($2.24 billion), International Paper ($2.04 billion), Tractor Supply ($1.96 billion), Coinbase Global, Inc. ($1.93 billion), Moderna, Inc. ($1.91 billion), and SoFi Technologies, Inc. ($1.84 billion). View all of the most shorted stocks.

Short selling CRXM is an investing strategy that aims to generate trading profit from Gene Biotherapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Gene Biotherapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CRXM, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CRXM, twice per month. The most recent reporting period available is October, 15 2024.